Yahoo
NasdaqCM - Nasdaq Real Time Price USD

BioLineRx Ltd. (BLRX)

1.9500 -0.0400 (-2.01%)
As of 12:54:16 PM EST. Market Open.
Chart Range Bar
Loading chart for BLRX
  • Previous Close 1.9900
  • Open 1.9400
  • Bid 2.2000 x 100
  • Ask 2.3100 x 100
  • Day's Range 1.9400 - 1.9500
  • 52 Week Range 1.9400 - 3.9500
  • Volume 3,914
  • Avg. Volume 16,928
  • Market Cap (intraday) 9.708M
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) --
  • EPS (TTM) 0.0000
  • Earnings Date (est.) Nov 23, 2026
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est 22.00

BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

www.biolinerx.com

20

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is TA-125 (^TA125.TA) .

YTD Return

BLRX
32.06%
TA-125 (^TA125.TA)
7.35%

1-Year Return

BLRX
43.80%
TA-125 (^TA125.TA)
0.00%

3-Year Return

BLRX
96.81%
TA-125 (^TA125.TA)
130.56%

5-Year Return

BLRX
98.28%
TA-125 (^TA125.TA)
99.65%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 294k
Earnings -3.03M
Profit Margin -1,029.25%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-3M
-2M
-1M
0
-1000.0%
-800.0%
-600.0%
-400.0%

Analyst Insights

View More

Analyst Price Targets

18.00
22.00 Average
1.9500 Current
26.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 6/17/2025
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 26 -> 26

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -19.82%

  • Return on Equity (ttm)

    -55.27%

  • Revenue (ttm)

    1.39M

  • Net Income Avi to Common (ttm)

    -6.99M

  • Diluted EPS (ttm)

    0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    13.08M

  • Total Debt/Equity (mrq)

    47.78%

  • Levered Free Cash Flow (ttm)

    -8.85M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: